Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibrutinib + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Pharmacyclics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ibrutinib + pembrolizumab is an investigational combination therapy consisting of two distinct agents with complementary mechanisms of action. Ibrutinib is a first-in-class, orally administered small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) and also inhibits Interleukin-2-inducible T-cell Kinase (ITK), modulating B-cell receptor signaling and skewing immune responses toward a Th1 phenotype. Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance anti-tumor T-cell activity. The rationale for combining these drugs lies in the potential for synergistic anti-cancer effects by both directly inhibiting tumor cell survival pathways and enhancing anti-tumor immunity. This combination has been evaluated in phase 1/2 clinical trials for metastatic colorectal cancer, chronic lymphocytic leukemia, mantle cell lymphoma, advanced melanoma, and other hematologic malignancies[1][2][3][6].
- Brand names
- Imbruvica + Keytruda
- Other names
- ibrutinib and pembrolizumabpembrolizumab and ibrutinib
02
Targets
ITK (Interleukin 2-inducible T-cell kinase)BTK (Bruton tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ibrutinib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibrutinib + pembrolizumab.